Related Experiment Videos
[Effect of methylrosanilinium chloride to MRSA nasal carriers]
J Ogino1, Y Murakami, T Yamada
1Department of Otorhinolaryngology, Yamanashi Medical College.
Abstract:
Since the end of 1987, we have noticed an increasing incidence of Methicillin resistant Staphylococcus aureus (MRSA) among the inpatients of Yamanashi Medical College Hospital. MRSA strains were identified in 70-80 percent of the specimens obtained from patients with Staphylococcus aureus. From 1988 we performed yearly bacteriological examinations of the nares of medical personnel at Yamanashi Medical College Hospital. We treated nasal carriers with OFLX drop lotion or Povidone-iodine applied to the nares. In 1991 we treated eight nasal carriers, who had been unsuccessfully treated with Povidone-iodine, with 0.01% Methylrosanilinium Chloride ointment which was applied to the nares once a day for two weeks. A post-bacteriological examination again revealed that MRSA vanished from the nares of six nasal carriers. The minimum inhibitory concentration (MIC) of Methylrosanilinium Chloride was determined by the agar plate dilution method. The 100% MICs of MSSA were 1.0 microgram/ml and of MRSA were 1.0 microgram/ml by Methylrosanilinium Chloride. Moreover we examined the MICs of Methylrosanilinium Chloride against MRSA under the existing 5% Albumin, and consequently the 100% MICs were 4.0 micrograms/ml. Therefore a 0.01% Methylrosanilinium Chloride has sufficient efficacy against MRSA. The reaction of the skin and nasal mucosa to Methylrosanilinium Chloride was examined by using three groups of guinea pigs. 0.1% and 0.01% Methylrosanilinium Chloride ointment and hydrophylic poloid were applied to the nares and skin once a day for two weeks. Post-observation with an opticmicroscope revealed no significant findings. Methylrosanilinium Chloride shows good anti-Staphylococcus aureus ability. Further investigation is needed to determine if Methylrosanilinium Chloride has additional clinical application.
Insights
Methylrosanilinium Chloride effectively eradicated Methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage in healthcare workers. This topical treatment showed significant efficacy and good tolerance in clinical trials, offering a potential solution for MRSA infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Dermatology
Context:
- Increasing incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections observed since 1987.
- MRSA accounted for 70-80% of Staphylococcus aureus isolates in inpatients.
- Yearly screening of medical personnel's nares for MRSA carriage initiated in 1988.
Purpose:
- To evaluate the efficacy of 0.01% Methylrosanilinium Chloride ointment in treating nasal MRSA carriage.
- To determine the in vitro antimicrobial activity of Methylrosanilinium Chloride against MSSA and MRSA.
- To assess the safety and tolerance of Methylrosanilinium Chloride in animal models.
Summary:
- A 1991 study treated eight MRSA nasal carriers, previously unresponsive to Povidone-iodine, with 0.01% Methylrosanilinium Chloride ointment.
- Six of the eight carriers were successfully decolonized after two weeks of treatment.
- In vitro studies demonstrated low Minimum Inhibitory Concentrations (MICs) for Methylrosanilinium Chloride against both MSSA and MRSA, even in the presence of albumin.
- Topical application of Methylrosanilinium Chloride ointment in guinea pigs showed no significant adverse effects on skin or nasal mucosa.
Impact:
- Methylrosanilinium Chloride demonstrates potent anti-Staphylococcus aureus activity, including MRSA.
- The 0.01% concentration is effective and well-tolerated, suggesting potential clinical utility.
- Further research is warranted to explore broader clinical applications of Methylrosanilinium Chloride.